BPC-157, an abbreviation of Body Protection Compound-157, is a synthetic peptide that has become a recurring subject in the laboratory literature on tissue and signalling research. Cataloged as a research chemical, it is characterized by a defined amino-acid sequence and a well-documented molecular profile. This overview summarizes what BPC-157 is, its reported origin, its analytical identity, and the categories of investigation that preclinical and in vitro studies have historically examined, described strictly as areas of scientific study rather than as outcomes.

What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide, meaning it is a short chain composed of 15 amino acids. Its sequence corresponds to a partial fragment derived from a naturally occurring human gastric protein. Because it is assembled through solid-phase peptide synthesis rather than extracted from tissue, laboratory-grade material can be produced to a consistent, defined composition suitable for analytical and experimental work. Within research catalogs it is listed alongside other short peptides as a reference compound for study, such as this BPC-157 listing.

As a synthetic fragment, BPC-157 belongs to the broader family of sequence-defined peptides that researchers use to probe cellular and molecular questions. For general background on how this class of compounds is defined and categorized, see our overview of what research peptides are.

Molecular Identity

BPC-157 is defined by a specific and reproducible set of analytical parameters. Reporting these values accurately is central to material characterization and quality control in a research setting.

  • Chemical name: Body Protection Compound-157 (a pentadecapeptide)
  • CAS number: 137525-51-0
  • Molecular formula: C62H98N16O22
  • Molecular weight: approximately 1419.5 g/mol
  • Class: synthetic peptide (15 amino acids)

These identifiers allow laboratories to confirm compound identity using techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry, where the measured mass can be compared against the theoretical molecular weight.

Origin and Sequence

The sequence associated with BPC-157 is reported to correspond to a fragment of a protein found in human gastric juice. Researchers describe it as a partial sequence rather than the full parent protein, which is one reason it is prepared synthetically for study. Because the compound is produced through defined chemical synthesis, its identity does not depend on biological extraction, and its amino-acid order can be verified analytically.

As a sequence-defined synthetic peptide, BPC-157 is valued in the laboratory setting primarily as a reproducible, well-characterized reference compound for controlled experimental work.

Research History

BPC-157 has appeared in the scientific literature for several decades, initially in the context of gastrointestinal and tissue-related research models. Over time it became a frequently referenced compound in preclinical and cell-based investigations, which is reflected in its assignment of a formal CAS registry number and its inclusion in peptide research catalogs. The accumulation of published preclinical work is largely why the compound remains a common subject of continued laboratory characterization today.

Areas Examined in the Research Literature

Preclinical and in vitro studies involving BPC-157 have examined a range of biological questions. The items below describe categories of investigation that appear in the published literature and are presented neutrally as topics of study, not as demonstrated effects or outcomes.

  • Angiogenesis-related signalling: researchers have investigated pathways associated with blood-vessel formation in cell and animal models.
  • Gastrointestinal tissue models: in keeping with the sequence's reported gastric origin, various gut-tissue models have been used to study the compound.
  • Tendon and fibroblast cell studies: in vitro work has examined fibroblast behavior and connective-tissue cell cultures.
  • General tissue-model research: additional preclinical models have been used to characterize the peptide's interactions at the cellular level.

Across these areas, the published work is confined to laboratory and animal-model settings. None of it is described here as an outcome, and it does not describe or imply any application in humans.

BPC-157 in Research Blends

In the research-catalog context, BPC-157 is frequently studied alongside TB-500, another peptide that appears in the tissue and signalling literature. Combining sequence-defined peptides in a single research preparation is a common approach for laboratories investigating how multiple compounds behave under shared experimental conditions. Examples in this category include a BPC-157 & TB-500 blend and a three-component BPC-157, TB-500 & GHK-Cu blend.

For a companion overview of the peptide most often paired with BPC-157 in these preparations, see our TB-500 research overview.

Research-use-only notice: BPC-157 and all related materials described here are intended strictly for in vitro laboratory research and experimental study. They are not drugs, foods, cosmetics, or dietary supplements, and nothing in this article should be interpreted as describing use in humans or animals, or as offering medical, therapeutic, or diagnostic guidance of any kind.